Auris Health, previously known as Auris Surgical Robotics, has been named to to CNBC’s Disruptor 50 list, and is the only medical device company to be included.
The Redwood City, Calif.-based company was selected due to its focus on lung cancer, which CNBC said kills more individuals in the US than any other type of cancer, and its founder, robotic surgical pioneer and intuitive surgical founder Dr. Frederic Moll.
The company has already raised $513 million in equity capital from major tech investors and recently won FDA approval for its robotic Monarch Platform.
Topping the list are Elon Musk’s SpaceX, ridesharing service Uber and Airbnb. Other health-related plays on the list include genetic profiler 23andMe, Oscar Health, Ginkgo Bioworks and Veritas Genetics, according to the CNBC report.
Earlier this month, Auris Health said it inked a cooperative development and commercialization deal with Johnson & Johnson (NYSE:JNJ) division Ethicon’s NeuWave Medical subsidiary looking to develop systems for the robotically-assisted bronchoscopic ablation of lung lesions.